Photodynamic Therapy Plus Root Debridement in Gum Disease Treatment V2 (PDTV2)
A Split-mouth Randomised Controlled Clinical Trial of Photodynamic Therapy (PDT) as Adjunctive Therapy to Root Surface Debridement (RSD), Compared to RSD Alone in the Treatment of Residual Periodontal Pockets in Patients With Chronic Periodontitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S10 2JF
- Sheffield Teaching Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients ≥ 30 years old
- Presence of at least 20 remaining teeth
- Patients diagnosed with moderate to severe chronic periodontitis, according to Armitage 1999 classification
- Have undergone a minimum of one cycle of full mouth nonsurgical root surface debridement.
- A minimum of 8 residual periodontal pockets (≥4mm) per patient and a maximum of 24. Amongst these, at least one site per half mouth must exhibit pocket depths of ≥ 6 mm.
- Pockets distribution should allow for split mouth design using sextants in a diagonal orientation.
- Received no active periodontal treatment for the last three months.
- Full mouth plaque score and full mouth bleeding score ≤ 30%.
- Sites in the other half of the mouth to be separated by one or more teeth (avoids photosensitising agent affecting the other half).
Exclusion Criteria:
- Patients with systemic diseases that may alter the response to treatment and healing in periodontal diseases.
- Pregnancy and lactation.
- The use of systemic or local antibiotic in the past three months.
- The need for antibiotic prophylaxis before periodontal treatment.
- Use of antimicrobial mouth rinses in the preceding two months.
- The use of any pharmacological agents that could influence the study outcome or inflammatory indicators (e.g. patients currently on photosensitizing medications).
- Confirmed or suspected allergy or hypersensitivity to methylene blue.
- Confirmed or suspected allergy or hypersensitivity to chlorhexidine.
- Confirmed or suspected allergy or hypersensitivity to polymethyl methacrylate (PMMA).
- Patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Inability to perform proper oral hygiene due to physical impairment.
- Patients unable to consent for themselves.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: root surface debridement (RSD)
Standard care - root surface debridement (RSD)
|
|
|
Active Comparator: light activated dye (PDT)
light activated dye photodynamic therapy (PDT)
|
light activated dye photodynamic therapy-PDT to periodontal pockets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pocket depth change
Time Frame: 3 months
|
The difference in mean change of probing pocket depth in millimetres between the test and control sites
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in clinical attachment
Time Frame: 3 months
|
The difference in mean change of clinical attachment loss in millimetres between the test and control sites.
|
3 months
|
|
Bleeding on probing
Time Frame: 3 months
|
The percentage difference of bleeding on probing between tests and controls.
|
3 months
|
|
Probing depths originally ≥ 6mm.
Time Frame: 3 months
|
The percentage difference of sites with probing depths originally ≥ 6mm.
|
3 months
|
|
Probing depths originally ≤3mm
Time Frame: 3 months
|
The percentage increase of sites with probing depths originally ≤3mm
|
3 months
|
|
Number of sites improving by ≥2mm
Time Frame: 3 months
|
The total number of sites improving by ≥2mm
|
3 months
|
|
Percentage of sites improving by ≥2mm
Time Frame: 3 months
|
The percentage of sites improving by ≥2mm
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gareth Griffiths, University of Sheffield
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STH19404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
NCT07293962RecruitingPeriodontitis | Periodontitis Chronic Generalized Moderate | Periodontitis (Stage 3) | Periodontitis, Adult | Periodontitis Chronic Generalized Severe | Periodontitis, Chronic | Periodontitis Stage II | Periodontitis Chronic Localized Slight | Periodontitis Stage III
-
NCT07505251Not yet recruitingPeriodontitis Stage II | Periodontitis Stage III | Periodontitis Stage IV
-
NCT07590089CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II | Periodontitis Stage III
-
NCT07599657RecruitingPeriodontitis | Periodontitis Stage II | Periodontitis Stage III
-
NCT07517991CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II
-
NCT06675578Not yet recruitingStage IV Periodontitis | Advanced Periodontitis | Stage III Periodontitis
-
NCT04264624CompletedPeriodontitis, Aggressive | Periodontitis, Adult
-
NCT07443410RecruitingPeriodontitis (Stage 3) | Periodontitis, Adult | Periodontitis Stage IV
-
NCT07549633Not yet recruitingPeriodontitis (Stage 3) | Periodontitis Stage IV
-
NCT07272980CompletedPeriodontitis (Stage 3) | Periodontitis Stage III
Clinical Trials on light activated dye photodynamic therapy (PDT)
-
NCT01668823CompletedRecurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer
-
NCT00470496CompletedRecurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
-
NCT02119728WithdrawnRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage II Verrucous Carcinoma of the Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
-
NCT02004600Withdrawn
-
NCT05245045Recruiting
-
NCT03052127CompletedOcular Melanoma | Uveal Melanoma | Choroidal Melanoma
-
NCT04301999CompletedCholangiocarcinoma
-
NCT02409732Completed
-
NCT05171894RecruitingPort-Wine Stain | Nevus Flammeus | Port-wine Birthmarks
-
NCT06939400Not yet recruitingGlioblastoma Multiforme (GBM)